{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:12:41Z","timestamp":1771481561362,"version":"3.50.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Project of Administration of Traditional Chinese Medicine of Guangdong Province of China","award":["20232010"],"award-info":[{"award-number":["20232010"]}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To compare the efficacy of intravitreal ranibizumab (IVR) and conbercept (IVC) treatment for retinopathy of prematurity (ROP) and to evaluate the risk factors associated with disease reactivation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective study, the medical records of infants with ROP treated with IVR or IVC from April 2017 to June 2024 at Guangdong Women and Children Hospital were reviewed. The primary outcome measures were reactivation rate, time to reactivation, and factors associated with reactivation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 294 infants (565 eyes) were included. The reactivation rate was 10.39% (43 of 414 eyes) in the IVR group and 12.58% (19 of 151 eyes) in the IVC group, with no significant difference between the two groups (\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.46). The mean time to reactivation was similar between the IVR group (8.92 \u00b1 2.01 weeks) and the IVC group (8.78 \u00b1 1.68 weeks) (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.84). Multivariate logistic regression analysis identified that a lower postmenstrual age (PMA) at initial treatment (\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.001) and Zone I ROP (\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.008) were significant independent risk factor of reactivation. Gestational age, birth weight, sex, and other systemic comorbidities were not significantly associated with reactivation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ranibizumab and conbercept are effective for treating ROP. A lower PMA at initial treatment and Zone I ROP were identified as significant risk factors for reactivation. Infants with these characteristics require closer and more prolonged follow-up after anti-VEGF therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1754490","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:23:32Z","timestamp":1771478612000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and factors associated with reactivation following intravitreal ranibizumab or conbercept for retinopathy of prematurity"],"prefix":"10.3389","volume":"13","author":[{"given":"Qiuhui","family":"Liu","sequence":"first","affiliation":[{"name":"Guangdong Women and Children Hospital","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Guangdong Women and Children Hospital","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiafen","family":"Liu","sequence":"additional","affiliation":[{"name":"Guangdong Women and Children Hospital","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzhen","family":"Xie","sequence":"additional","affiliation":[{"name":"Guangdong Women and Children Hospital","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge","family":"Mu","sequence":"additional","affiliation":[{"name":"Guangdong Women and Children Hospital","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanhuan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Guangdong Women and Children Hospital","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Zheng","sequence":"additional","affiliation":[{"name":"Guangdong Women and Children Hospital","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuelin","family":"Huang","sequence":"additional","affiliation":[{"name":"Guangdong Women and Children Hospital","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxun","family":"Wang","sequence":"additional","affiliation":[{"name":"Guangdong Women and Children Hospital","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","article-title":"Retinopathy of prematurity","volume":"382","author":"Hellstrom","year":"2013","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e2021053924","DOI":"10.1542\/peds.2021-053924","article-title":"Retinopathy of prematurity: a global perspective and recent developments","volume":"150","author":"Sabri","year":"2022","journal-title":"Pediatrics"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1167\/iovs.64.7.11","article-title":"Associations of Vegf polymorphisms with retinopathy of prematurity","volume":"64","author":"Ling","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.survophthal.2024.02.005","article-title":"Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: a network meta-analysis","volume":"69","author":"Ortiz-Seller","year":"2024","journal-title":"Surv Ophthalmol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (Rainbow): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2025-327597","article-title":"Reactivation of retinopathy of prematurity after anti-Vegf treatment: a review","author":"Kumawat","year":"2025","journal-title":"Br J Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.oret.2022.02.006","article-title":"Time course of retinopathy of prematurity regression and reactivation after treatment with Ranibizumab or laser in the Rainbow trial","volume":"6","author":"Fleck","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e248383","DOI":"10.1001\/jamanetworkopen.2024.8383","article-title":"Intravitreal Aflibercept vs laser therapy for retinopathy of prematurity: two-year efficacy and safety outcomes in the nonrandomized controlled trial Firefleye next","volume":"7","author":"Stahl","year":"2024","journal-title":"JAMA Netw Open"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s10792-022-02480-6","article-title":"Comparison of adverse events between intravitreal anti-Vegf and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review","volume":"43","author":"Tsiropoulos","year":"2023","journal-title":"Int Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1038\/s41433-021-01814-5","article-title":"Clinical outcome following reinjection of Ranibizumab for reactivation of retinopathy of prematurity","volume":"36","author":"Bassiouny","year":"2022","journal-title":"Eye (Lond)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1167\/iovs.16-20680","article-title":"Recurrence of retinopathy of prematurity after Intravitreal Ranibizumab monotherapy: timing and risk factors","volume":"58","author":"Lyu","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","article-title":"Reactivation of retinopathy of prematurity after ranibizumab treatment","volume":"35","author":"Wong","year":"2015","journal-title":"Retina"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.18240\/ijo.2023.01.14","article-title":"Recurrence risk factors of intravitreal ranibizumab monotherapy in retinopathy of prematurity: a retrospective study at one center","volume":"16","author":"Wu","year":"2023","journal-title":"Int J Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1097\/IAE.0000000000001763","article-title":"Short-term outcomes after Intravitreal injections of Conbercept versus Ranibizumab for the treatment of retinopathy of prematurity","volume":"38","author":"Jin","year":"2018","journal-title":"Retina"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1136\/bjophthalmol-2020-318026","article-title":"Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomised controlled trial","volume":"106","author":"Wu","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.oret.2017.11.012","article-title":"Analysis of the recurrence of plus disease after intravitreal ranibizumab as a primary monotherapy for severe retinopathy of prematurity","volume":"2","author":"Arambulo","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ophtha.2016.10.032","article-title":"Efficacy of primary Intravitreal Ranibizumab for retinopathy of prematurity in China","volume":"124","author":"Feng","year":"2017","journal-title":"Ophthalmology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e001173","DOI":"10.1136\/bmjophth-2022-001173","article-title":"Comparison of intravitreal injection of ranibizumab versus bevacizumab for treatment of type 1 and aggressive retinopathy of prematurity in rural Egypt. A randomized clinical trial","volume":"1","author":"Tawfik","year":"2022","journal-title":"BMJ Open Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4103\/joco.joco_193_21","article-title":"Comparison of clinical outcomes of Intravitreal bevacizumab and Aflibercept in type 1 Prethreshold retinopathy of prematurity in posterior zone ii","volume":"34","author":"Eftekhari Milani","year":"2022","journal-title":"J Curr Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40001-024-02206-7","article-title":"Effect and factors associated with reactivation after intravitreal conbercept or aflibercept in retinopathy of prematurity","volume":"30","author":"Huang","year":"2025","journal-title":"Eur J Med Res"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40942-021-00334-4","article-title":"Comparison of aflibercept and bevacizumab in the treatment of type 1 retinopathy of prematurity","volume":"7","author":"Riazi-Esfahani","year":"2021","journal-title":"Int J Retina Vitreous"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1001\/jama.2022.10564","article-title":"Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity: the Firefleye randomized clinical trial","volume":"328","author":"Stahl","year":"2022","journal-title":"JAMA"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00417-018-4168-5","article-title":"Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity","volume":"257","author":"Sukgen","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"10732","DOI":"10.1038\/s41598-018-28987-6","article-title":"A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity","volume":"8","author":"Cheng","year":"2018","journal-title":"Sci Rep"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s10792-021-02188-z","article-title":"Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment","volume":"42","author":"Suren","year":"2022","journal-title":"Int Ophthalmol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1586\/17512433.2015.1075879","article-title":"Conbercept (Kh-902) for the treatment of neovascular age-related macular degeneration","volume":"8","author":"Nguyen","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.ophtha.2017.03.018","article-title":"Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors","volume":"124","author":"Huang","year":"2017","journal-title":"Ophthalmology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12886-018-0815-1","article-title":"Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab","volume":"18","author":"Tong","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1097\/IAE.0000000000003196","article-title":"Factors associated with reactivation after Intravitreal bevacizumab or Ranibizumab therapy in infants with retinopathy of prematurity","volume":"41","author":"Iwahashi","year":"2021","journal-title":"Retina"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s10792-021-02198-x","article-title":"Intravitreal bevacizumab to treat retinopathy of prematurity in 865 eyes: a study to determine predictors of primary treatment failure and recurrence","volume":"42","author":"Fadakar","year":"2022","journal-title":"Int Ophthalmol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"113913","DOI":"10.1016\/j.jpeds.2024.113913","article-title":"Clinical risk factors for retinopathy of prematurity reactivation after intravitreal antivascular endothelial growth factor injection","volume":"273","author":"Lee","year":"2024","journal-title":"J Pediatr"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1097\/IAE.0000000000002663","article-title":"Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy","volume":"40","author":"Ling","year":"2020","journal-title":"Retina"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1754490\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:23:33Z","timestamp":1771478613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1754490\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":33,"alternative-id":["10.3389\/fmed.2026.1754490"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1754490","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"article-number":"1754490"}}